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Abstract
Background
Despite the introduction of direct-acting antiviral agents for chronic hepatitis C virus (HCV)
infection, peginterferon alfa/ribavirin remains relevant in many resource-constrained set-
tings. The non-randomized GUARD-C cohort investigated baseline predictors of safety-
related dose reductions or discontinuations (sr-RD) and their impact on sustained virologic
response (SVR) in patients receiving peginterferon alfa/ribavirin in routine practice.
Methods
A total of 3181 HCV-mono-infected treatment-naive patients were assigned to 24 or 48
weeks of peginterferon alfa/ribavirin by their physician. Patients were categorized by time-
to-first sr-RD (Week 4/12). Detailed analyses of the impact of sr-RD on SVR24 (HCV RNA
<50 IU/mL) were conducted in 951 Caucasian, noncirrhotic genotype (G)1 patients
assigned to peginterferon alfa-2a/ribavirin for 48 weeks. The probability of SVR24 was iden-
tified by a baseline scoring system (range: 0–9 points) on which scores of 5 to 9 and <5 rep-
resent high and low probability of SVR24, respectively.
Results
SVR24 rates were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3% (203/
396), respectively, in G1, 2, 3, and 4 patients. Overall, 16.9% and 21.8% patients
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experienced ≥1 sr-RD for peginterferon alfa and ribavirin, respectively. Among Caucasian
noncirrhotic G1 patients: female sex, lower body mass index, pre-existing cardiovascular/
pulmonary disease, and low hematological indices were prognostic factors of sr-RD;
SVR24 was lower in patients with ≥1 vs. no sr-RD byWeek 4 (37.9% vs. 54.4%; P =
0.0046) andWeek 12 (41.7% vs. 55.3%; P = 0.0016); sr-RD byWeek 4/12 significantly
reduced SVR24 in patients with scores <5 but not ≥5.
Conclusions
In conclusion, sr-RD to peginterferon alfa-2a/ribavirin significantly impacts on SVR24 rates
in treatment-naive G1 noncirrhotic Caucasian patients. Baseline characteristics can help
select patients with a high probability of SVR24 and a low probability of sr-RD with peginter-
feron alfa-2a/ribavirin.
Introduction
Several direct-acting antivirals (DAAs) have been approved for the treatment of chronic hepa-
titis C and interferon-free regimens are now available [1–3]. These new agents increase sus-
tained virologic response (SVR) rates, shorten the required duration of therapy for most
patients, and are well tolerated. However, market access for these new therapies is limited in
many countries [1,2,4,5]. Thus, despite major advances in the treatment paradigm for chronic
hepatitis C, the combination of peginterferon alfa/ribavirin will continue to be used where
access to these new DAAs is restricted.
Optimal use of peginterferon alfa/ribavirin involves careful patient selection prior to initiat-
ing treatment and close monitoring of the on-treatment virologic response. An important
aspect of treatment with peginterferon alfa/ribavirin is the management of adverse events,
since these lead to treatment discontinuation in more than 10% of patients [6]. Adverse events
and laboratory abnormalities are managed initially by reducing the dose of peginterferon alfa
and/or ribavirin and thus the result is reduced exposure to treatment. Reduced exposure to
treatment in general, and to ribavirin in particular, is associated with lower SVR rates; thus,
adverse events and dose reductions can have a significant impact on treatment efficacy [7–9].
Here, we report the results of a large, international, noninterventional cohort (GUARD-C)
that was undertaken with the objective of identifying baseline predictors of safety-related dose
reductions or discontinuations (sr-RD) to manage adverse events and laboratory abnormalities
and the impact of sr-RD on SVR rates in patients receiving peginterferon alfa/ribavirin in rou-
tine clinical practice.
Materials and Methods
Study Design
GUARD-C is an international, prospective, non-randomized, observational cohort study in
patients with chronic hepatitis C receiving peginterferon alfa/ribavirin combination therapy
(ClinicalTrials.gov Identifier: NCT01344889). The first patient was enrolled on October 14,
2009 and the last patient completed follow-up on June 27, 2013. The study was registered with
ClinicalTrials.gov on April 27, 2011. The delay in registration occurred because observational
studies started before January 1, 2010 were not required to be registered. Thus, the decision to
register the trial was taken on a voluntary basis. The authors confirm that all ongoing and
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Patients
Adult patients (males and non-pregnant females) with chronic hepatitis C and quantifiable
serum hepatitis C virus (HCV) RNA levels receiving treatment with peginterferon alfa/ribavi-
rin according to the standard of care and the product license were eligible for enrollment after
providing informed consent. Patients with contraindications to peginterferon alfa/ribavirin or
with end-stage renal disease, and/or recipients of major organ transplants, were not eligible for
the study. Enrollment in the study and the dose and duration of treatment were at the discre-
tion of the investigator. Overall, 4453 patients were recruited into the GUARD-C program and
a total of 3181 treatment-naive patients with HCV mono-infection were enrolled and followed
up between October 2009 and June 2013 as follows: Albania (n = 46), Algeria (n = 15), Bahrain
(n = 23), Belgium (n = 211), Bosnia-Herzegovina (n = 41), Brazil (n = 138), Egypt (n = 92),
Greece (n = 175), India (n = 86), Iran (n = 60), Italy (n = 1001), Kuwait (n = 22), Lebanon
(n = 28), Macedonia (n = 74), Pakistan (n = 90), Poland (n = 311), Portugal (n = 76), Qatar
(n = 145), Romania (n = 333), Serbia (n = 50), Slovakia (n = 50), South Korea (n = 83), and the
United Arab Emirates (n = 31). Additional sites in Hungary did not recruit any treatment-
naive patients, and the study was suspended in Morocco before recruiting any patients.
The protocol conformed to guidelines for good pharmacoepidemiology practices [10] and
the ethical guidelines of the 1975 Declaration of Helsinki. The protocol was approved by local
independent ethics committees at each site. Full names of the approving ethics committees for
each site can be found in S1 File. The ethics committees approved the protocol between August
14, 2009 and March 28, 2011. All patients provided informed written informed consent.
Treatment
The planned treatment duration and dosing with peginterferon alfa/ribavirin were determined
at the treating physician’s discretion according to the local standard of care and the local sum-
mary of product characteristics. Peginterferon alfa-2a solution is administered once-weekly by
subcutaneous injection and ribavirin tablets are administered orally twice daily usually for a
period of 24 or 48 weeks. Study drugs were self-administered by outpatients enrolled in the
study.
Assessments
Laboratory and clinical assessments were performed according to routine clinical practice and
in accordance with the local standard of care. Safety and efficacy data were documented in an
electronic case report form (eCRF) during treatment and follow-up.
Outcomes
The primary efficacy endpoint was SVR24, defined as HCV RNA<50 IU/mL (as measured by
a commercially available polymerase chain reaction assay) after 24 weeks of untreated follow-
up (≥140 days after last dose of treatment). The analysis was conducted according to the inten-
tion-to-treat principle: patients with missing SVR24 values were considered nonresponders.
Relapse was defined as HCV RNA ≥50 IU/mL during untreated follow-up in a patient with an
end-of-treatment virologic response.
Safety of Peginterferon Alfa Plus Ribavirin
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Rapid virologic response (RVR) was defined as a virologic response (HCV RNA<50 IU/
mL) by Week 4. Complete early virologic response (cEVR) was defined as a virologic response
by Week 12, but no RVR. Partial early virologic response (pEVR) was defined as a ≥2-log10
reduction in HCV RNA byWeek 12 in a patient with no RVR or cEVR.
The primary safety endpoint of the trial was the time to first sr-RD of peginterferon alfa or
ribavirin. The time will be calculated as days from first study treatment to the day of the first
dose reduction or discontinuation due to safety reasons. If a patient discontinues the study
treatment for any other reasons, then the time will be considered censored at the last treatment
day. Patients were categorized by the time to first occurrence of sr-RD (no sr-RD or ≥1 sr-RD
in the first 4 or 12 weeks of treatment) in order to assess the impact of sr-RDs on SVR24 rates.
Statistical Analysis
It was assumed that the rate of sr-RD would be in the range of 20 to 40%; that the standard
deviation of explanatory covariates included in the Cox proportional hazard model would
range from 0.4 to 0.5 (after conversion of units) and that a risk reduction of 25% (equivalent to
a hazard ratio of 0.75) for a 1-unit change in a covariate should be detected with 80% power.
Since multiple covariates were to be included into the Cox regression model, an R2 of 0.1 to 0.2
was assumed for the multiple regression of a covariate on other covariates. On the basis of
these assumptions, a sample size of 2500 evaluable patients would be required to detect a haz-
ard ratio of 0.75 with 80% power at a significance level of 0.05. To account for patients with
missing values, a sample size of 3000 patients was planned.
A total of 4453 patients were enrolled in GUARD-C and 4354 received at least one dose of
study drug; however, this analysis was restricted to treatment-naive HCV mono-infected
patients who were assigned to 24 or 48 weeks of treatment with peginterferon alfa-2a or -2b
plus ribavirin (Fig 1). Patients with acute hepatitis C were excluded, as were those patients with
chronic hepatitis C who were assigned to treatment durations longer than 48 weeks, those who
had received prior treatment for chronic hepatitis C, those who had received other treatment
regimens or had switched between treatment regimens, and/or those patients who were co-
infected with hepatitis B virus or human immunodeficiency virus (HIV). Sub-analyses were
performed in two sub-groups: 1) treatment-naive HCV mono-infected genotype (G) 1 patients
(cirrhotic and noncirrhotic); and 2) treatment-naive HCV mono-infected Caucasian, noncir-
rhotic G1 patients, both of which populations were assigned to 48 weeks of treatment with
peginterferon alfa-2a/ribavirin. The rationale for these sub-analyses is that G1 is the most com-
mon and difficult-to-treat HCV genotype, and that 48 weeks is the recommended duration of
treatment with peginterferon alfa/ribavirin in patients with G1 infection [6]. A patient selection
tool for Caucasian, noncirrhotic G1 patients treated for 48 weeks with peginterferon alfa-2a/
ribavirin has been developed by Ferenci et al. [11]; thus, the analysis in subgroup 2 was
intended to evaluate this patient selection tool in a separate population. Moreover, a meta-anal-
ysis has shown that there is a significant difference in SVR rates between patients treated with
peginterferon alfa-2a and those treated with alfa-2b [12], and between different races (espe-
cially if host IL28B genotype is unknown) [13].
Subgroups considered in addition to the two subpopulations of G1 patients, included
patients who did and did not receive at least 80% of the planned dose of peginterferon alfa-2a
and ribavirin and who were treated for at least 80% of the planned treatment duration (“80/80/
80”); and patients categorized by the time to first sr-RD using two different cutoffs (by Week 4
and by Week 12). Numbers and frequencies of variables of interest were calculated for sub-
group analyses and associations between variables of interest (e.g. SVR) were investigated by
tests of association (Pearson chi-square, Fisher’s exact test).
Safety of Peginterferon Alfa Plus Ribavirin
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Cox proportional hazards analysis was used to identify baseline characteristics associated
with time to the first sr-RD. Time to the first sr-RD was calculated in days from the first day of
study treatment to the day at which the first sr-RD occurred. The time was censored at the last
treatment day for patients who did not have any sr-RD.
The impact of sr-RD on SVR24 rates was assessed in subpopulation 2 (Caucasian, noncirrhotic
G1 patients assigned to 48 weeks of peginterferon alfa-2a/RBV). In addition, the utility of a modi-
fied prediction tool for identifying Caucasian, noncirrhotic G1 patients with a high probability of
achieving SVR24 with 48 weeks of treatment with peginterferon alfa-2a/ribavirin was assessed [11].
The modified scoring system involves five baseline factors (Table 1) and differs from that of
Ferenci et al. [11] in that serum aspartate aminotransferase (AST) levels are not included because
this parameter was not collected on the eCRF. The total score for an individual patient is the sum
of the scores assigned for each of the five variables and ranges from 0–9, with higher scores indi-
cating more favorable characteristics for achieving an SVR24. In this analysis, patients were cate-
gorized as having scores<5 and ≥5. A multiple logistic regression analysis was also performed to
identify baseline and on-treatment factors associated with SVR24 in this population. Factors
included in this analysis are listed in S1 Table. This analysis was performed after excluding
patients who discontinued treatment for efficacy or other non-safety reasons, to avoid the misin-
terpretation that a shorter duration of treatment was responsible for the lack of an SVR24, when
in fact the absence of early virological response was responsible for the short treatment duration.
The analyses were done with SAS version 8.2 software (SAS Institute Inc., Cary, NC, USA)
with the exception of the exploratory analyses. These were performed with SAS version 9.2
software.
Fig 1. Enrollment and patient disposition. aOther reasons (more than one reason may apply to a given patient): no final confirmation from the investigator
(n = 56); contraindications to therapy (n = 15); HCV RNA-negative at screening/baseline (n = 12); end-stage renal disease (n = 7); major organ
transplantation (n = 2); not treated with peginterferon alfa (n = 1) or ribavirin (n = 2); acute hepatitis C (n = 1); co-infection with HIV (n = 115); co-infection with
HBV (n = 74); treatment with regimen other than peginterferon alfa-2a/ribavirin or peginterferon alfa-2b/ribavirin (n = 14); treatment-naive and intended
treatment duration of 72 weeks (n = 6).
doi:10.1371/journal.pone.0151703.g001
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Results
Patients
Overall, a total of 3181 treatment-naive patients with HCV mono-infection were enrolled in 25
countries, assigned to a planned treatment duration of 24 or 48 weeks and treated with pegin-
terferon alfa/ribavirin and followed up between October 2009 and June 2013 (Fig 1). The base-
line characteristics for all patients are shown in S2 Table (patients treated with peginterferon
alfa-2a/ribavirin) and S3 Table (patients treated with peginterferon alfa-2b/ribavirin).
The majority of patients had HCV G1 infection (1634/3181; 51.7%)–92% of whom (1497/
1634) were assigned to 48 weeks of treatment with peginterferon alfa-2a/ribavirin (Table 2).
The mean age of these patients was 47.4 years and the majority were male (53.8%), Caucasian
(92.7%), and had a baseline HCV RNA level>800,000 IU/mL (53.1%). Approximately 30% of
these patients had transition to cirrhosis or cirrhosis, and 19% and 3% had a history of cardio-
vascular and pulmonary disease, respectively.
The baseline characteristics of the 951 patients in subgroup 2 were similar to those in the
overall G1 population with respect to sex, age, weight, body mass index, HCV RNA level, and
laboratory test results (Table 2).
The number of patients in whom treatment with peginterferon alfa and ribavirin was pre-
maturely withdrawn is shown in S4 Table for the total patient population (25.4% and 26.0%,
respectively), subgroup 1 (28.7% and 29.2%, respectively), and subgroup 2 (24.8% and 25.2%,
respectively). Insufficient therapeutic response was the most common reason for premature
withdrawal from peginterferon alfa-2a in the total patient population (9.5%), and in subgroups
1 (13.3%) and 2 (10.4%). Rates of premature withdrawal from treatment with peginterferon
Table 1. Scoring system used to identify patients in subgroup 2a with a high or low probability of
achieving SVR24.
Predictor Scoreb
Age, years 35 2
>35 but 45 1
>45 0
Body mass index, kg/m2 20 2
>20 but 22 1
>22 0
HCV RNA, IU/mL 100,000 3
>100,000 but 400,000 2
>400,000 but 800,000 1
>800,000 0
Platelet count, x 109/L >150 1
150 0
ALT/ULNc >3 1
3 0
aHCV G1, treatment-naive, Caucasian, noncirrhotic patients assigned to 48 weeks of treatment with
peginterferon alfa-2a.
bThe total score for an individual patient is the sum of the scores assigned for each of the ﬁve variables and
ranges from 0–9 with higher scores indicating more favorable characteristics. If one or more variable scores
are missing for a patient, the total score is missing.
cAlanine aminotransferase (ALT) value divided by the upper limit of normal (ULN) for the local laboratory.
doi:10.1371/journal.pone.0151703.t001
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alfa and ribavirin for safety reasons in the total patient population (5.5% and 6.0%, respec-
tively), and in subgroup 1 (6.4% and 6.9%, respectively) and subgroup 2 (5.6% and 6.0%) were
similar.
Table 2. Baseline characteristics of patients included in the analyses.
Characteristic All patients Genotype 1 patients assigned to peginterferon alfa-2a/RBV
for 48 weeks
Subgroup 1 All Subgroup 2 Noncirrhotic, Caucasian
N = 3181 n = 1497 n = 951
Male sex, n (%) 1930 (60.7) 806 (53.8) 519 (54.6)
Race, n (%)
Caucasian/White 2767 (87.0) 1388 (92.7) 951 (100)
Black 60 (1.9) 20 (1.3) 0
Asian/Oriental 340 (10.7) 76 (5.1) 0
Other 14 (0.4) 13 (0.9) 0
Mean age ± SD, years 46.0 ± 12.8 47.4 ± 12.5 45.1 ± 12.8
Mean body mass index ± SD, kg/m2 26.0 ± 4.3 25.9 ± 4.2 25.7 ± 4.0
Method to assess liver ﬁbrosis
Biopsy 1479 (46.5) 915 (61.1) 570 (59.9)
Noninvasive 907 (28.5) 343 (22.9) 206 (21.7)
Best guess/Not assessed 795 (25.0) 239 (16.0) 175 (18.4)
Patients with cirrhosis/transition to cirrhosisa 758/3174 (23.9) 460/1494 (30.8) 0
Mean HCV RNA ± SD, log10 IU/mL 5.78 ± 0.86 5.87 ± 0.79 5.89 ± 0.77
HCV RNA >800,000 IU/mL, n (%) 1575 (50.2) 790 (53.1) 506 (53.7)
History of cardiovascular disease, n (%) 488 (15.3) 286 (19.1) 144 (15.1)
History of pulmonary disease, n (%) 96 (3.0) 46 (3.1) 24 (2.5)
History of diabetes mellitus, n (%) 282 (8.9) 139 (9.3) 57 (6.0)
History of thyroid disease, n (%) 175 (5.5) 92 (6.1) 57 (6.0)
History of psychiatric disease/symptoms, n (%) 233 (7.3) 103 (6.9) 54 (5.7)
Mean hemoglobin concentration ± SD, g/L 151.1 ± 13.8 151.6 ± 13.5 152.0 ± 13.2
Mean neutrophil count ± SD x 109/L 3.6 ± 1.7 3.6 ± 1.8 3.7 ± 1.4
Mean platelet count ± SD x 109/L 205.0 ± 67.6 203.8 ± 67.2 216.5 ± 61.2
Mean ALT activity ± SD, IU/L 118.3 ± 99.6 116.5 ± 95.7 109.7 ± 92.9
Mean ALT ratio ± SD 2.15 ± 1.81 2.12 ± 1.74 2.00 ± 1.69
HCV genotype, n (%)
1 1634 (51.7) 1497 (100) 951 (100)
2 362 (11.5) 0 0
3 756 (23.9) 0 0
4 396 (12.5) 0 0
5/6 10 (0.3) 0 0
Planned treatments, n (%)
PegIFN alfa-2a/RBV 2845 (89.4) 1497 (100) 951 (100)
PegIFN alfa-2b/RBV 336 (10.6) - -
24 weeks 1091 (34.3) - -
48 weeks 2090 (65.7) 1497 (100) 951 (100)
aAssessed by biopsy, noninvasive testing, or best guess.
ALT, alanine aminotransferase; SD, standard deviation.
doi:10.1371/journal.pone.0151703.t002
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Efficacy: SVR24 Rates
In the overall population, stratified by HCV genotype, the SVR24 rates for patients with HCV
G1, 2, 3, and 4 infection were 46.1% (754/1634), 77.1% (279/362), 68.0% (514/756), and 51.3%
(203/396), respectively. Virologic response and relapse rates by treatment regimen and geno-
type are presented in S5 and S6 Tables.
In the overall population, SVR24 rates were higher in patients who received at least 80% of
the planned dose of peginterferon alfa-2a and ribavirin and who were treated for at least 80%
of the planned treatment duration (“80/80/80”) (1496/2182, 68.6%) than in those who did not
fulfill the “80/80/80” rule (279/998, 28.0%).
Among the 951 patients in subgroup 2, the SVR24 rate was 52.9% (503/951). For those who
fulfilled the “80/80/80” rule, the SVR24 rate was 66.0% (426/645). In contrast, the SVR24 rate
was 25.2% (77/305) in patients who did not meet these criteria (exposure data were unavailable
for one patient) (Pearson chi-square P<0.0001). However, this latter group includes patients
who discontinued treatment prematurely for any reason and, in particular, patients who dis-
continued treatment for lack of efficacy.
Safety-Related Dose Reductions or Discontinuations (sr-RD)
The incidences of sr-RD of peginterferon alfa in the overall population, and in subgroups 1 and
2 were 16.9%, 21.3%, and 18.4%, respectively, and the incidences of sr-RD for ribavirin were
21.8%, 29.5%, and 28.5%, respectively (S7 Table). The most common causes of a first sr-RD of
peginterferon alfa-2a were neutropenia (6.9%, 9.2%, and 8.1%, respectively), thrombocytopenia
(3.5%, 5.3%, and 3.7%, respectively), anemia (1.2%, 1.1%, and 0.9%, respectively), and asthenia
(1.0%, 1.5%, and 1.5%, respectively), and the most common causes of a first sr-RD of ribavirin
were anemia (13.1%, 18.8%, and 18.2%, respectively), decreased weight (2.0%, 3.1%, and 3.4%,
respectively), and asthenia (0.9%, 1.1%, and 1.2%, respectively).
Baseline factors significantly associated with earlier occurrence of a first sr-RD of peginter-
feron or ribavirin in the overall population included female sex, older age, lower body mass
index, G1/4 vs. 2/3, presence of pre-existing cardiovascular or pulmonary diseases, lower
hemoglobin concentration, and lower platelet and neutrophil counts (Fig 2A). The incidence
of sr-RD increased in proportion to the number of baseline risk factors for sr-RD (Fig 3A).
Conversely, the SVR24 rate was highest in patients without risk factors for sr-RD (72.1%) and
lowest in patients with ≥6 risk factors for sr-RD (26.1%, Fig 3B).
Baseline factors associated with time to first sr-RD in subgroup 2 were similar to those in
the overall population with the exception of genotype (not applicable) and age (Fig 2B).
Exposure to treatment and the time of occurrence of sr-RD have an impact on SVR rates as
shown in Table 3. When the timing of the first sr-RD was superimposed on the “80/80/80” rule
there was a substantial difference in SVR rates, with the higher SVR rates in patients who did
not have an early dose reduction. For example, among patients who fulfilled the “80/80/80”
rule SVR rates are higher in those who did not have an sr-RD in the first 4 weeks (68.9% vs.
60.3%) or first 12 weeks (69.7% vs. 57.4%).
Impact of sr-RD on SVR24 Rates in HCV G1 Patients Treated for 48
WeeksWith Peginterferon Alfa-2a/Ribavirin (Subgroups 1 and 2)
Among the patients in subgroup 1, the SVR24 rate was significantly higher than in those who
did not report an sr-RD byWeek 4 of treatment (48.6% vs. 35.2% in patients with ≥1 sr-RD by
Week 4, P = 0.0026) or by Week 12 of treatment (50.1% vs. 36.1% ≥1 sr-RD byWeek 12,
P<0.0001) (Fig 4A).
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Similarly, among patients in subgroup 2, the SVR24 rate was significantly higher in those
with no sr-RD byWeek 4 or 12 than in those with at least one sr-RD (by Week 4: 54.4% vs.
37.9%, P = 0.0046; by Week 12: 55.3% vs. 41.7%, P = 0.0016) (Fig 4B). SVR24 rates in patients
with the first sr-RD in Weeks 0–4,>4–12, and>12 weeks were 37.9% (33/87), 45.7% (37/81),
and 61.9% (104/168), respectively.
Fig 2. Cox proportional hazards analysis for time to first safety-related dose reductions or discontinuations in patients treated for 24 or 48 weeks
with peginterferon alfa-2a or alfa-2b and ribavirin. (A) All treatment-naive patients (G1–6) assigned to 24 or 48 weeks of treatment with peginterferon alfa-
2a or alfa-2b/RBV (N = 3181); (B) Subgroup 2: treatment-naive Caucasian, G1 noncirrhotic patients assigned to 48 weeks of treatment with peginterferon
alfa-2a/RBV (n = 951).
doi:10.1371/journal.pone.0151703.g002
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SVR24 Rates by Baseline Score (Subgroup 2)
Among the 951 patients included in subgroup 2, the baseline scoring system was useful in strat-
ifying patients with a low and high chance of achieving SVR24 (S7 Table). A total of 161 and
756 individuals had baseline predictive scores ≥5 and<5, respectively. As expected, the SVR24
rate was higher in patients with more favorable predictive scores (≥5) than in those with less
favorable predictive scores (<5) (73.3% [118/161] vs. 49.1% [371/756], P<0.0001). Among
patients with predictive scores ≥5, SVR24 rates were numerically but not statistically signifi-
cantly higher in patients who experienced no sr-RD in the first 4 or 12 weeks than in patients
Fig 3. Incidence of safety-related dose reductions or discontinuations (sr-RD) (A) and SVR24 rates (B)
according to the number of baseline risk factors for sr-RD in the overall population (N = 2881). Patients
with missing data (n = 300) for risk factors were excluded (BMI n = 18; HCV genotype n = 23; baseline
hemoglobin n = 45; baseline platelets n = 56; baseline neutrophils n = 245). Baseline risk factors for sr-RD
based on results of Cox proportional hazards analysis include: female sex, age >50 years, body mass index
22 kg/m2, HCV G1 or 4 infection, presence of cardiovascular disease, presence of pulmonary disease,
hemoglobin140 g/L, platelets115 x 109/L, neutrophils2.0 x 109/L.
doi:10.1371/journal.pone.0151703.g003
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who experienced ≥1 sr-RD in the first 4 (73.8% vs. 66.7%) or 12 weeks (75.6% vs. 61.5%) (Fig
5). However, among patients with baseline scores<5, SVR24 rates were significantly higher in
those who experienced no sr-RD in the first 4 or 12 weeks than in patients who experienced ≥1
sr-RD byWeek 4 (50.7% vs. 33.8%, P = 0.0068) and by Week 12 (51.5% vs. 38.0%, P = 0.0045)
(Fig 5).
SVR rates were also higher in patients with baseline scores of ≥5 than<5 regardless of
whether the “80/80/80” rule was fulfilled (Table 4). Thus, in patients fulfilling the “80/80/80”
rule, SVR rates were 83.0% in those with a baseline prediction score ≥5 and 63.1% in those with
a prediction score<5. In patients who did not fulfill the “80/80/80” rule, SVR rates were 51.0%
and 20.3% respectively.
Early sr-RDs (i.e. within the first 12 weeks) were associated with lower SVR24 rates in this
population (P = 0.0316 for overall effect; Fig 5) (patients who discontinued for non-safety rea-
sons were excluded from the logistic regression analysis). Other factors significantly associated
with lower SVR24 rates included older age, lower baseline hemoglobin concentration, no on-
treatment virologic response (no RVR, cEVR, or pEVR), and more than 20% missed days of
treatment with ribavirin (Fig 6).
Safety
Among the 3181 treatment-naive patients the overall incidence of adverse events (AEs) and
serious adverse events (SAEs) was 71.1% and 5.9%, respectively (S8 Table). A total of 11
patients (0.3%) died during the study. The most common AEs were anemia (25.1%), asthenia
(16.2%), decreased weight (15.6%), neutropenia (15.2%), and thrombocytopenia (12.7%) (S9
Table).
The adverse event profile in treatment-naive G1 patients assigned to 48 weeks of treatment
with peginterferon alfa-2a/ribavirin profile was similar to that of the overall population,
although the incidence of AEs, SAEs, and individual event rates were somewhat higher. The
incidences of anemia, asthenia, decreased weight, neutropenia, and thrombocytopenia were
34.5%, 21.1%, 20.3%, 21.4%, and 20.0% respectively (S9 Table).
Discussion
The safety and efficacy of dual peginterferon alfa/ribavirin therapy observed in GUARD-C are
consistent with the results of previous large randomized trials and cohort studies. The overall
SVR24 rates of 55.8% (all genotypes combined) and 46.1% in the G1 population is very similar
to that achieved in the Phase 3 registration trials [14–16]. The higher SVR24 rate in G1 patients
assigned to 48 weeks’ treatment with peginterferon alfa-2a/ribavirin (47.3%) than in those
Table 3. SVR rates according to exposure and time of first sr-RD in the overall population.
Patient subgroup “80/80/80” rule fulﬁlled
(N = 2182)a
“80/80/80” rule NOT fulﬁlled
(n = 998)b
SVR No SVR SVR No SVR
sr-RD in ﬁrst 4 weeks No 1452/2109 (68.9) 657/2109 (31.1) 228/836 (27.3) 608/836 (72.7)
Yes 44/73 (60.3) 29/73 (39.7) 51/162 (31.5) 111/162 (68.5)
sr-RD in ﬁrst 12 weeks No 1384/1987 (69.7) 603/1987 (30.3) 169/674 (25.1) 505/674 (74.9)
Yes 112/195 (57.4) 83/195 (42.6) 110/324 (34.0) 214/324 (66.0)
aReceived ≥80% of planned drug dosages and were treated for at least 80% of the planned duration.
bReceived <80% of planned drug dosages and/or were treated for less than 80% of the planned duration.
doi:10.1371/journal.pone.0151703.t003
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Fig 4. SVR24 rates by incidence of safety-related dose reductions or discontinuations byWeek 4 andWeek 12 of treatment in genotype 1 patients
assigned to 48 weeks of treatment with peginterferon alfa-2a/ribavirin. Fisher’s exact test, two-sided P-value. (A) Subgroup 1: all treatment-naive
genotype 1 patients (n = 1497); (B) Subgroup 2: treatment-naive, genotype 1, noncirrhotic Caucasian patients (n = 951).
doi:10.1371/journal.pone.0151703.g004
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receiving peginterferon alfa-2b/ribavirin (28.8%) supports the results of a comprehensive
meta-analysis of randomized trials [12]. The overall rate of treatment withdrawal among G1
patients assigned to 48 weeks of treatment with peginterferon alfa-2a/ribavirin was approxi-
mately 25% in the present study, which is similar to the rate reported in Phase 3 studies of
peginterferon alfa-2a/ribavirin (30%) [15,16]. In this subgroup, the most common reasons
for withdrawal of treatment with peginterferon alfa-2a in the present study were lack of efficacy
(10%) and safety (6%).
Fig 5. SVR24 rates by baseline predictive score and by incidence of safety-related dose reductions or discontinuations byWeek 4 andWeek 12 of
treatment in subgroup 2 (Caucasian, treatment-naive, G1 noncirrhotic patients assigned to 48 weeks of treatment with peginterferon alfa-2a/
ribavirin). Fisher’s exact test, two-sided P-value. Please note that 34 patients had unknown baseline score.
doi:10.1371/journal.pone.0151703.g005
Table 4. SVR rates according to exposure and baseline prediction score in subgroup 2.
Patient subgroup “80/80/80” rule fulﬁlled (N = 621)a “80/80/80” rule not fulﬁlled (n = 295)b
SVR No SVR SVR No SVR
Baseline prediction score <5 321/509 (63.1) 188/509 (36.9) 50/246 (20.3) 196/246 (79.7)
≥5 93/112 (83.0) 19/112 (17.0) 25/49 (51.0) 24/49 (49.0)
aReceived ≥80% of planned drug dosages and were treated for at least 80% of the planned duration)
bReceived <80% of planned drug dosages and/or were treated for less than 80% of the planned duration).
doi:10.1371/journal.pone.0151703.t004
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Importantly, this analysis from GUARD-C shows that baseline factors can be used to iden-
tify patients at increasing risk for sr-RD, and that sr-RD has an impact on SVR24 rates. Factors
associated with sr-RD in the overall population (G1–6) included female sex, older age, lower
body mass index, HCV G1/4 vs. 2/3, the presence of cardiovascular and pulmonary disease and
low hematological indices (hemoglobin, neutrophils, platelets). The same factors were associ-
ated with sr-RD in Caucasian noncirrhotic HCV G1 patients with the exception of age (and
genotype). To our knowledge, this association between sr-RD and pre-existing pulmonary and
cardiovascular disease is a novel finding.
Not surprisingly, the incidence of sr-RD increased in proportion to the number of risk fac-
tors for sr-RD. Among patients with no risk factors the incidence of sr-RD was approximately
7% and among those individuals with at least six risk factors for sr-RD the incidence was
approximately 74%. Conversely, SVR24 rates were highest in patients with no risk factors for
sr-RD (72.1%) and were lowest in patients with at least six risk factors for sr-RD (26.1%).
There is a broad overlap between risk factors for sr-RD and factors predictive of lower
SVR24 rates. For example, here G1 or 4 infection was identified as a predictor of higher sr-RD
rates, while it is also a well-established predictor of lower SVR24 rates. Consistently lower
SVR24 rates are achieved in patients infected with G1 or 4 as compared with G2 or 3 [6].
Increasing age was associated with increasing sr-RD rates in this analysis and has been associ-
ated with lower SVR24 rates [17]. Conversely, here, higher body mass index was associated
with lower sr-RD rates, while higher body mass index is typically associated with lower SVR24
rates [18]. This may be the result of lower exposure to drug in heavier patients. A higher inci-
dence of certain hematological events with increased exposure to ribavirin and peginterferon
alfa-2a has been reported elsewhere [19].
On the basis of this analysis, a physician will be able to evaluate a patient for peginterferon
alfa-2a therapy by considering, on the one hand, a set of factors associated with efficacy (SVR)
and, on the other hand, a set of factors associated with safety (sr-RD). Unique factors related to
sr-RD identified in this analysis include hematological parameters and the presence of cardio-
vascular and pulmonary disease.
Hematological abnormalities are important adverse events associated with peginterferon
alfa/ribavirin treatment. Anemia was the most common adverse event reported during the
present study and was the most common event associated with a first sr-RD of ribavirin.
Fig 6. Multiple logistic regression analysis of baseline and on-treatment factors associated with SVR24 in Caucasian, treatment-naive, G1,
noncirrhotic patients assigned to 48 weeks of treatment with PegIFN alfa-2a/RBV. Patients who discontinued therapy for efficacy or other non-safety
reasons were excluded. aEffect P-value: P = 0.0316 for sr-RD and 0.0001 for missed ribavirin days in percentage of target.
doi:10.1371/journal.pone.0151703.g006
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Neutropenia, thrombocytopenia, and anemia were the three most common events associated
with a first sr-RD of peginterferon alfa in the overall analysis. Moreover, decreasing hemoglo-
bin, platelet, and neutrophil levels at baseline were all significantly associated with earlier
occurrence of sr-RD in the Cox proportional hazards analysis, both in the overall population
and in the subgroup of noncirrhotic Caucasian patients with HCV G1 infection.
The relationship between hematological parameters and safety and efficacy outcomes is
complex. Anemia is a common complication of dual peginterferon alfa/ribavirin treatment.
For example, approximately one-third of patients have hemoglobin levels<10 g/dL at some
point during a 48-week course of treatment [20]. Anemia is a common cause of dose reduc-
tions, particularly of ribavirin, and reduced exposure to ribavirin as a result of physician-initi-
ated dose reductions and non-adherence by patients is associated with significant reductions in
SVR24 rates [7–9].
Paradoxically, patients with large decreases in hemoglobin (e.g.>3 g/dL) have higher
SVR24 rates than patients with lesser decreases in hemoglobin [9,21]. It has been suggested
that the drop in hemoglobin is a marker of the strength of the response to treatment. This
interpretation is supported by data that show that marginal decreases in platelet and white
blood cell counts during treatment are associated with nonresponse [22].
The patient selection (SVR24 predictor) tool used in this analysis was based on one devel-
oped using data from Caucasian, treatment-naive G1 patients enrolled in a large noninterven-
tional observational study (PROPHESYS) [11]. We included all parameters used in the original
version [11] with the exception of AST, which was not recorded on the eCRF in our study. The
incorporation of the predictive score in the current analysis shows that the impact of early sr-
RD on SVR24 rates is most important in patients with an unfavorable baseline predictive score.
For example, the occurrence of ≥1 sr-RD in the first 4 weeks of treatment in a patient with an
unfavorable baseline score (<5) was associated with a significant reduction in the SVR24 rate
(from 50.7% in patients with no sr-RD to 33.8% in patients with ≥1 sr-RD). In contrast, among
patients with a favorable baseline score (≥5), the SVR24 rates in patients with an sr-RD
(66.7%) and without one (73.8%) in the first 4 weeks of treatment were not significantly differ-
ent. This may indicate that, in patients with favorable characteristics, dose reductions have
only a minimal impact upon response rates.
The multiple logistic regression analysis of factors associated with SVR24 shows that
achievement of an on-treatment virologic response (RVR or cEVR) was the most important
positive predictor of SVR24. The occurrence of sr-RD during Weeks>4–12 was a significant
negative predictor of SVR24. The occurrence of a first sr-RD in the first 4 weeks of treatment
showed a similar trend but was not significant, which could be due to the small number of
patients and slightly different response rates.In contrast, a first occurrence of an sr-RD after
Week 12 was not a negative predictor for SVR24. Furthermore, missing ≥20% of the targeted
days of treatment with ribavirin had a marked negative association with achievement of
SVR24, while missing<20% of the targeted days of treatment with ribavirin did not have a
negative effect on SVR24. This suggests that longer treatment interruptions or early permanent
discontinuations due to safety reasons have a strong impact on SVR24 rates, while early dose
reductions or short interruptions are less critical, subject to the condition that the patient
received treatment for more than 80% of the target treatment days.
Patient selection is increasingly important in the treatment of chronic hepatitis C. Several
DAAs are now available, and interferon-free regimens with consistently high cure rates are
now a reality [2]. However, although recently approved and pending DAA-containing regi-
mens are highly effective and have good safety profiles, they are unlikely to be universally avail-
able due to high acquisition costs [2,3,5]. For this reason dual peginterferon/ribavirin therapy
is likely to remain a viable option in resource-limited settings. For clinicians who continue to
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use dual therapy in their practice, it is important that they remain able to make informed deci-
sions about the suitability of treatment for a given patient. This analysis provides practical
information that can be used to inform such decisions. An individual patient’s characteristics
can be reviewed prior to baseline to evaluate whether they are likely to achieve an SVR24 with
dual therapy, and whether they are likely to experience an sr-RD.
Limitations of this study include those typical of cohort studies and retrospective analyses.
The number of non-Caucasian patients and patients with frank cirrhosis was low, a fact which
places limits on the generalizability of the results. Host IL28B genotype is the most important
baseline predictor of response to peginterferon alfa [12]. As such, host genotype provides very
useful information when planning treatment with peginterferon alfa/ribavirin; however, IL28B
genotype is not routinely available in resource-limited settings where dual therapy is most
likely to be used. The patient selection tool of Ferenci et al. [11] does not include liver biopsy
results, and analysis of subgroup 2 in the present study specifically excluded patients with cir-
rhosis. However, as patients with cirrhosis are a group in urgent need of treatment, it seems
reasonable to say that these individuals should be given a high priority for treatment with
DAA-containing regimens including interferon-free combinations, regardless of their baseline
predictive score. Our application of the prediction score by Ferenci et al. [11] did not include
one of the prediction factors (serum AST ratio at baseline); however, the modified score was
still able to differentiate patients with high and low chances of SVR.
In conclusion, the results of GUARD-C show that it is possible to identify patients at risk of
sr-RD by using simple and readily available data regarding baseline characteristics, and that it
is possible to predict the extent of the risk for sr-RD. sr-RDs have a negative impact on the
probability of achieving an SVR, especially if they occur within the first 12 weeks of treatment.
Moreover, the results suggest that early dose reductions or interruptions are less critical than
longer interruptions or permanent discontinuations for achievement of SVR24 in noncirrhotic
Caucasian patients with G1 infection, provided that ribavirin is administered for>80% of the
targeted number of treatment days. Finally, the modified baseline score will help to identify
those patients with a high likelihood for SVR. The results will be of particular interest to clini-
cians with limited access to DAAs and those who continue to use dual therapy with peginter-
feron alfa-2a/ribavirin.
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